CTOs on the Move

Walking Fish Therapeutics

www.walkingfishtx.com

 
Walking Fish Therapeutics, Inc. is a privately held biotechnology company discovering and developing innovative therapeutics that harness the power of B cells as protein factories and immune modulators. Walking Fish has created a broad technology platform addressing enzyme replacement therapies, oncology, autoimmune disease, and recombinant antibody production. The company`s first program, WFX-001, employs B cells as protein factories to generate a deficient enzyme in Fabry disease. Founded in 2019 by Lewis (Rusty) Williams, MD, PhD, the former CSO of Chiron, co-founder of Cor Therapeutics and founder and Chief Executive Officer of Five Prime Therapeutics, the company has assembled a diverse ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.walkingfishtx.com
  • 450 East Jamie Court Suite 300
    South San Francisco, CA USA 94080
  • Phone: 650.392.0422

Executives

Name Title Contact Details
Nallakkan Arvindan
Chief Technology Officer Profile

Similar Companies

Cephazone Pharma

Cephazone Pharma is a Pomona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DRX

DRX is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

X4 Pharmaceuticals

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.

Pharmacosmos

Pharmacosmos A/S is specialized in iron therapy. We develop, manufacture and market medicines for treatment of iron deficiency anaemia in humans and animals.

Stratus Pharmaceuticals

Stratus Pharmaceuticals is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.